Cargando…
Borderline epithelial tumors of the ovary: Experience of 55 patients
The objective of the present study was to evaluate the clinicopathological features and the survival time estimates in patients treated for borderline ovarian tumors (BOTs). A retrospective review of all patients treated for BOTs at the University of Bari (Bari, Italy) between 1991 and 2011 was perf...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301501/ https://www.ncbi.nlm.nih.gov/pubmed/25621067 http://dx.doi.org/10.3892/ol.2014.2758 |
_version_ | 1782353653811642368 |
---|---|
author | LOIZZI, VERA SELVAGGI, LUIGI LEONE, LUCA LATORRE, DONATELLA SCARDIGNO, DORIANA MAGAZZINO, FRANCESCAPAOLA CORMIO, GENNARO |
author_facet | LOIZZI, VERA SELVAGGI, LUIGI LEONE, LUCA LATORRE, DONATELLA SCARDIGNO, DORIANA MAGAZZINO, FRANCESCAPAOLA CORMIO, GENNARO |
author_sort | LOIZZI, VERA |
collection | PubMed |
description | The objective of the present study was to evaluate the clinicopathological features and the survival time estimates in patients treated for borderline ovarian tumors (BOTs). A retrospective review of all patients treated for BOTs at the University of Bari (Bari, Italy) between 1991 and 2011 was performed. Data were obtained from hospital records and gynecological oncology charts. A total of 55 patients were identified. The median age was 40 years (range, 13–79 years). The majority of the patients (85.5%) exhibited International Federation of Obstetrics and Gynecology (FIGO) stage I disease and the remainder exhibited FIGO stage II/III (7.3% in each stage). Serous histology was found in 60.0% of the cases and an elevation of the cancer antigen-125 serum level occurred in 23.6% of the cases. All patients underwent surgery and 3.7% received chemotherapy. In total, 10.9% exhibited recurrence and the median survival rate was 39 months. The median survival time and the five-year survival rate were 42 months (range, 16–84 months) and 97%, respectively. Therefore, BOTs have an excellent prognosis. Conservative surgery should be considered for patients of reproductive age who desire preservation of fertility. A long-term follow-up is highly recommended for these tumors. |
format | Online Article Text |
id | pubmed-4301501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-43015012015-01-23 Borderline epithelial tumors of the ovary: Experience of 55 patients LOIZZI, VERA SELVAGGI, LUIGI LEONE, LUCA LATORRE, DONATELLA SCARDIGNO, DORIANA MAGAZZINO, FRANCESCAPAOLA CORMIO, GENNARO Oncol Lett Articles The objective of the present study was to evaluate the clinicopathological features and the survival time estimates in patients treated for borderline ovarian tumors (BOTs). A retrospective review of all patients treated for BOTs at the University of Bari (Bari, Italy) between 1991 and 2011 was performed. Data were obtained from hospital records and gynecological oncology charts. A total of 55 patients were identified. The median age was 40 years (range, 13–79 years). The majority of the patients (85.5%) exhibited International Federation of Obstetrics and Gynecology (FIGO) stage I disease and the remainder exhibited FIGO stage II/III (7.3% in each stage). Serous histology was found in 60.0% of the cases and an elevation of the cancer antigen-125 serum level occurred in 23.6% of the cases. All patients underwent surgery and 3.7% received chemotherapy. In total, 10.9% exhibited recurrence and the median survival rate was 39 months. The median survival time and the five-year survival rate were 42 months (range, 16–84 months) and 97%, respectively. Therefore, BOTs have an excellent prognosis. Conservative surgery should be considered for patients of reproductive age who desire preservation of fertility. A long-term follow-up is highly recommended for these tumors. D.A. Spandidos 2015-02 2014-12-02 /pmc/articles/PMC4301501/ /pubmed/25621067 http://dx.doi.org/10.3892/ol.2014.2758 Text en Copyright © 2015, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Articles LOIZZI, VERA SELVAGGI, LUIGI LEONE, LUCA LATORRE, DONATELLA SCARDIGNO, DORIANA MAGAZZINO, FRANCESCAPAOLA CORMIO, GENNARO Borderline epithelial tumors of the ovary: Experience of 55 patients |
title | Borderline epithelial tumors of the ovary: Experience of 55 patients |
title_full | Borderline epithelial tumors of the ovary: Experience of 55 patients |
title_fullStr | Borderline epithelial tumors of the ovary: Experience of 55 patients |
title_full_unstemmed | Borderline epithelial tumors of the ovary: Experience of 55 patients |
title_short | Borderline epithelial tumors of the ovary: Experience of 55 patients |
title_sort | borderline epithelial tumors of the ovary: experience of 55 patients |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4301501/ https://www.ncbi.nlm.nih.gov/pubmed/25621067 http://dx.doi.org/10.3892/ol.2014.2758 |
work_keys_str_mv | AT loizzivera borderlineepithelialtumorsoftheovaryexperienceof55patients AT selvaggiluigi borderlineepithelialtumorsoftheovaryexperienceof55patients AT leoneluca borderlineepithelialtumorsoftheovaryexperienceof55patients AT latorredonatella borderlineepithelialtumorsoftheovaryexperienceof55patients AT scardignodoriana borderlineepithelialtumorsoftheovaryexperienceof55patients AT magazzinofrancescapaola borderlineepithelialtumorsoftheovaryexperienceof55patients AT cormiogennaro borderlineepithelialtumorsoftheovaryexperienceof55patients |